HitGen

HitGen Financial Debt Ratio

The Financial Debt Ratio of HitGen (688222.SS) as of Nov 15, 2026 is 7.08 %. In the previous year, Financial Debt Ratio was 5.32 % — a change of 33.14% (higher).

Financial Debt Ratio

7.08 %

YoY

33.14%

Last updated:

Financial Debt Ratio of HitGen is 2025 7.08 % . Financial Debt Ratio of HitGen was 2024 5.32 % . It decreases by 33.14% higher compared to the previous year.

The HitGen Financial Debt Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Debt Ratio
Date
Financial Debt Ratio
Jan 1, 2017
0.00 CNY
Jan 1, 2018
4.90 CNY
Jan 1, 2020
6.00 CNY
Jan 1, 2021
11.33 CNY
Jan 1, 2022
11.83 CNY
Jan 1, 2023
11.20 CNY
Jan 1, 2024
5.32 CNY
Jan 1, 2025
7.08 CNY
The HitGen Financial Debt Ratio history
YEARFinancial Debt RatioYoY
7.08 %+33.14%
5.32 %-52.49%
11.20 %-5.37%
11.83 %+4.46%
11.33 %+88.76%
6.00 %+22.44%
4.90 %—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HitGen Stock analysis

What does HitGen do? HitGen Inc. generates revenue through DEL screening services, DEL library customization, chemical synthesis, and transfer of new drug R&D projects. The company serves pharmaceutical and biotechnology firms seeking to develop seed and lead compounds for drug discovery. Its domestic market focus includes clients in China, while international clients also access its DEL technology solutions. HitGen's services support the research and development phase of drug development, targeting companies in the pharmaceutical sector that require advanced compound libraries for early-stage drug discovery. The firm's DEL technology enables the creation of large compound libraries for high-throughput screening, which is critical for identifying potential drug candidates. HitGen's services are tailored to clients' needs, offering customized DEL libraries and synthesis support for drug development projects. Its business model relies on providing specialized R&D services to pharmaceutical companies that require efficient compound screening and lead optimization. HitGen's offerings include the research and creation of DEL technology, development of hit and lead compounds, and transfer of new drug R&D projects. The company's DEL screening services are a core product, allowing clients to identify promising compounds quickly. By focusing on DEL technology, HitGen positions itself as a key provider of specialized services for drug discovery in both domestic and international markets. HitGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HitGen stock

Financial Debt Ratio of HitGen is 7.08 % in 2025.

Financial Debt Ratio of HitGen changed from 5.32 % to 7.08 %, representing a 33.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Debt Ratio HitGen since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's HitGen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — HitGen

All Key Metrics — HitGen